1. Introduction {#sec1}
===============

Chimeric antigen receptor T cells (CAR-Ts) have recently been shown to improve treatment outcomes for B cell malignancies. High complete remission (CR) rates have been reported in several independent clinical trials of CAR-T treatment \[[@bib1], [@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7]\]. Recent studies have identified unique toxicities associated with CAR-T therapy, including cytokine release syndrome (CRS) and CAR-T-related encephalopathy syndrome \[[@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13]\]; however, cases of delayed idiopathic thrombocytopenic purpura (ITP) after CAR-T therapy have not been reported. We are the first to describe a case of successfully treated ITP that had been induced by CAR-T therapy in a relapsed/refractory multiple myeloma patient.

2. Case {#sec2}
=======

A 50-year-old male was diagnosed with IgD lambda multiple myeloma in July 2016 after presenting with anemia and chest pain. Induction therapy with one cycle of bortezomib, cyclophosphamide, and dexamethasone resulted in a partial response. He then received four cycles of bortezomib, lenalidomide, and dexamethasone and achieved a very good partial response, which was consolidated with autologous stem cell transplantation. Approximately 9 months later, the disease relapsed, and the patient was treated with one cycle of ixazomib, lenalidomide, and dexamethasone and three cycles of ixazomib, pomalidomide, and dexamethasone. However, the decrease in serum M-protein was only temporary. In 2018, the patient consented to participate in a clinical trial (ChiCTR--OIC--17011310) of anti-B cell maturation antigen (BCMA) CAR-T treatment. The patient provided written, informed consent, which included hematologic toxicity. On December 19, after lymphodepletion chemotherapy with fludarabine and cyclophosphamide, he was infused with 5.85 × 10^6^/kg of autologous T cells expressing an anti-BCMA-CAR construct ([Fig. 1](#fig1){ref-type="fig"}).Fig. 1Flow chart of the patient\'s treatment.Fig. 1

Within 24 h of infusion, the patient developed a high fever of up to 40 °C ([Fig. 2](#fig2){ref-type="fig"}C) and pancytopenia along with extremely elevated levels of serum C-reactive protein, D-dimer, interleukin (IL)-6, IL-10, and ferritin ([Fig. 2](#fig2){ref-type="fig"}B, D). Consequently, grade I CRS was diagnosed \[[@bib14]\]. His body temperature and white blood cell count returned to normal after 20 days, but the platelet count was low for over 1 month, necessitating frequent platelet transfusions ([Fig. 2](#fig2){ref-type="fig"}A). On January 23, 2019, the patient was discharged from the hospital with a platelet count of 23 × 10^9^/L. Assessment of his bone marrow aspirate by flow cytometry revealed that plasma cells were undetectable. Moreover, serum and urine M-protein assays were negative, indicating that the patient was in CR. His platelet count normalized 3 months after hospital discharge.Fig. 2Clinical course after B cell maturation antigen chimeric antigen receptor T cell (BCMA CAR-T) therapy. (A) White blood cell (WBC), neutrophil (NEU), and platelet (PLT) counts decreased after Car-T treatment. The former returned to a normal level after 1 month, whereas the latter took over 3 months to normalize. (B) Serum C-reactive protein (CRP), B-type natriuretic peptide (BNP), and creatinine (Cr) concentrations increased after Car-T treatment, then returned to normal levels. (C) The body temperature increased after Car-T treatment, then returned to normal. (D) Serum levels of interleukin (IL)-6, IL-10, ferritin, and D-dimer were elevated after Car-T treatment, then returned to normal levels.Fig. 2

On July 20, 2019, the patient presented with skin ecchymosis, without fever, fatigue, or pain. His platelet count had decreased to 1 × 10^9^/L, whereas the white blood cell count and hemoglobin level were normal. Bone marrow aspiration showed an absence of thrombogenic megakaryocytes ([Fig. 3](#fig3){ref-type="fig"}). Tests for antinuclear and antiphospholipid antibodies and hepatitis B and C were all negative. Secondary causes of thrombocytopenia, such as autoimmune diseases, lymphatic proliferative disease, bone marrow failure disorders, hematological malignancies, hypersplenism, and infection, were excluded. Due to bleeding symptoms and low platelet levels, the patient was treated at the local hospital, and data for other tests such as measurements of thrombopoietin and reticulated platelets were incomplete. Multiple myeloma was still in CR, as demonstrated by the absence of serum M-protein. The patient was treated with recombinant human thrombopoietin (15,000 U/day) and immunoglobulin (400 mg/kg/day) for 5 days. Glucocorticoids were not administered because the patient had undergone BCMA CAR-T therapy. The platelet count increased to 75 × 10^9^/L after 7 days of treatment ([Fig. 3](#fig3){ref-type="fig"}). Laboratory tests at the local hospital and successful treatment supported the diagnosis of ITP. One year after CAR-T therapy, the patient\'s multiple myeloma remained in CR without a relapse of ITP.Fig. 3Bone marrow and platelet count analyses. (a, b) Light microscopic images of a Wright\'s stained bone marrow aspirate of the patient before thrombopoietin and immunoglobulin treatment (10× and 100×, respectively). (c) Changes to the patient\'s platelet count after thrombopoietin and immunoglobulin treatment during the second hospitalization.Fig. 3

3. Discussion {#sec3}
=============

We are the first to report a case of ITP that arose in a patient with relapsed/refractory multiple myeloma after BCMA CAR-T therapy. The case was successfully treated with recombinant human thrombopoietin and immunoglobulin and without glucocorticoids. Thrombocytopenia is a clinical manifestation of CAR-T cell toxicity. Although conditioning chemotherapy regimens are known to contribute to the development of thrombocytopenia, Brudno et al. \[[@bib15]\] reported that in patients with high disease burdens, anti-CD19 CAR-T cells administered without chemotherapy could still cause cytopenia. Ali et al. \[[@bib16]\] reported that a patient with multiple myeloma experienced prolonged thrombocytopenia following BCMA CAR-T treatment. The authors proposed that high levels of cytokines, which are produced when anti-BCMA CAR T cells encounter a high multiple myeloma burden, and the bystander perforin/granzyme-mediated killing of hematopoietic cells might explain the observed effect. These mechanisms might have induced thrombocytopenia during our patient\'s first hospitalization. However, in contrast to that observed in our case, the patient reported by Ali et al. recovered 8 weeks after CAR-T cell infusion and showed no evidence of thrombocytopenia at follow-up.

In our study, the patient presented with ITP 7 months after BCMA CAR-T therapy, even though his platelet count had normalized 4 months earlier. Fried et al. \[[@bib17]\] reported late hematologic toxicity in 38 patients following CD19 CAR-T cell administration. They assumed that thrombocytopenia arises from two distinct mechanisms; the first event occurs following lymphodepleting therapy, whereas the second event seems unrelated to this. There may or may not be an interim recovery between these two phases. Of the patients treated with axicabtagene and ciloleucel for lymphoma, 7% had thrombocytopenia 3 months following the infusion \[[@bib18]\]. These reports are consistent with our case and further support the diagnosis of ITP. The patient had transient leukopenia in the later stage, considering the late hematological toxicity.

Although immune checkpoint inhibitors \[[@bib19]\] and vaccines \[[@bib20],[@bib21]\] can cause ITP, the pathophysiology of ITP is not fully understood. Molecular mimicry and/or immune provocation by specific antigen exposure that induces an autoimmune response against platelets in susceptible individuals might underlie the development of ITP \[[@bib22]\]. Until more data become available, patients receiving BCMA CAR-T therapy should be monitored for signs of ITP at follow-up.

The use of corticosteroids might impair the anti-leukemia function of CAR-T cells through the inhibition of T cell activation, resulting in attenuation of the therapeutic effect. In our case, we treated the patient with 15,000 U/day of recombinant human thrombopoietin and 400 mg/kg/day of immunoglobulin for 5 days. This regimen restored the platelet count to a normal level with no evidence of ITP relapse at 1-year follow-up. The present report raises awareness of delayed ITP as a complication of anti-BCMA CAR-T cell infusion and offers guidance to aid its diagnosis and treatment without compromising the therapeutic effect of CAR-T cell therapy. However, more extensive studies are needed to clarify the underlying pathophysiological mechanisms.
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